The Prostate Cancer Foundation 27th Annual Scientific Retreat to Cover Latest Discoveries in Prostate Cancer Research Including COVID-19 Link, Racial Disparities, and Clinical Advances
LOS ANGELES, Calif., October, 14, 2020 – The Prostate Cancer Foundation (PCF) announced today the program for its prestigious 27th Annual Scientific Retreat taking place October 20-23, 2020, which will be...Read More
Depend® brand partners with Mark Teixeira to announce Stand Strong for Men’s Health™ campaign benefitting the Prostate Cancer Foundation
NEENAH, Wis., Sept. 29, 2020 — In honor of Prostate Cancer Awareness Month, the Depend brand announced today its partnership with Major League Baseball (MLB) All-Star Mark Teixeira and the...Read More
The Prostate Cancer Foundation and Actor Harry Lennix Challenge Americans to “Eat It To Beat It” During Prostate Cancer Awareness Month
LOS ANGELES, Calif., August 18, 2020 – The Prostate Cancer Foundation (PCF) challenges Americans to show their support for men affected by prostate cancer by taking a simple challenge to eat...Read More
The Prostate Cancer Foundation and Robert F. Smith Announce New Effort to Address Health Disparities for African American Men
LOS ANGELES, Calif., July 21, 2020 – The Prostate Cancer Foundation (PCF) and Robert F. Smith, founder, chairman and CEO of Vista Equity Partners, announce a new effort to reduce...Read More
Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program
When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been...Read More
The Prostate Cancer Foundation Collaboration with Pan-Cancer Consortium Clarifies and Promotes Consistent Use of Common Terms for Biomarker and Germline Genetic Testing
LOS ANGELES, Calif., July 7, 2020 — The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish...Read More
New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer
PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have...Read More
ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment
A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track...Read More
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients...Read More
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical...Read More